Innovage Holding stock
INNVNASDAQInnovage Holding Corp., HealthcareISIN US45784A1043
58Score 58 out of 100, Neutral
Price and trend
66 / 100
Price history
+65% in one yearThe chart shows daily closes over 6 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 2.0% above it.
Since August 2025 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 48).
The price is 22% below its 52-week high. Largest decline in 6 years: 90% (March 2021 to April 2025).
Chart figures for advanced users
- SMA 50$9.54
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$9.22
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)48
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$4.79
- The lowest closing price of the last twelve months.
- Resistance$12.11
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Innovage Holding Corp. belongs to the Medical (Care Facilities) industry (United States) and, with a market value of $1.28B, is number 41 of 57 companies in its industry on MEQIRI.
- In fiscal 2026 it reported revenue of $989.71M (up 15.9% year on year) and a loss of $2.54M.
- MEQIRI Score 58 out of 100 (Neutral): rank 296 of 702 in Healthcare, median 53.
Show more
- Our model puts fair value at $7.37, with the price 28% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Earnings turn into cashFree cash flow above 500% of earnings over the last 12 months.Fundamentals 50
- More cash than debtCash $162.99M, financial debt $83.93M.Stability 64
Weaknesses
- Volatile share priceVolatility 69% a year over the last 12 months.Stability 64
Its standout strengths are momentum and capital allocation, while profitability and valuation hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 59 to 58.
The fundamentals are in the middle range.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among smaller stocks.
From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- high price swings
- price up very strongly over the past year
- weak fundamentals
Valuation
Valuation signal
Fairly valuedIn our model the price counts as cheap below $4.91 and expensive above $14.74 (uncertainty very high, based on the price swings of the past year).
The two parts of the fair value come to $13.46 (cash-flow model) and $1.29 (industry comparison), and the gap between them shows how uncertain the estimate is.
Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $6.21, at 7.8% it would be $9.12.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (19.6).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 15.5% on the twelve months before. Revenue has grown solidly since 2019, at about 11% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2026: gross 21%, operating 7%, net 0%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with low debt and comfortable interest coverage.
Earnings
- Next earnings
- 2 Feb 2027in 81 days
- Last reported
- 3 Nov 2026EPS reported $0.14 (expected $0.09)above expectations
Analyst estimates
- Earnings per share
- $0.47+6.1%
- Revenue
- $1.08B+0.3%
- Earnings per share
- $0.52+4.0%
- Revenue
- $1.16B+0.3%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: +2.6%For fiscal 2027 a net Medicare rate increase of 1.5% to 2.0% is expected, and earnings growth will depend more on execution.
“On Medicare, we currently expect our county rate increases adjusted for the continuing transition of the V28 risk adjustment model to result in a net rate increase of approximately 1.5% to 2.0%.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 8 Sep 2026 (fiscal Q4 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 3 insiders sold, $106.61M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Damato NicoleSale
22 Oct 2026, CHIEF LEGAL OFFICER
- Shares
- 3,402
- Price
- $9.51
- Value
- $32,353
- Tco Group Holdings, L.p., Ignite Aggregator Lp, Welsh, Carson, Anderson & Stowe XII, L.P.Sale
21 Oct 2026, Major holder
- Shares
- 1,500,000
- Price
- $9.25
- Value
- $13.88M
- Damato NicoleSale
25 Sept 2026, CHIEF LEGAL OFFICER
- Shares
- 23,814
- Price
- $8.70
- Value
- $207,182
Show 1 more
- Ignite Aggregator Lp, Tco Group Holdings, L.p.Sale
24 Sept 2026, Major holder
- Shares
- 10,000,000
- Price
- $9.25
- Value
- $92.5M
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Innovage Holding
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 58
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Care Facilities)
The next larger and next smaller companies by market value
- U.S. Physical TherapyUSPH $1.47B55
- Aevis VictoriaAEVS.SW $1.44B34
- AMN Healthcare ServicesAMN $1.44B65
- ClarianeCLARI.PA $1.37B39
- Pennant GroupPNTG $1.26B53
- Nutex HealthNUTX $1.18B73
- RHÖN-KLINIKUMRHK.DE $1.08B58
- Ramsay Générale de SantéGDS.PA $1.05B39
ETFs that hold Innovage Holding
Held by 2 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.01% | 0.30% | €4.28B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.01% | 0.30% | €2.22B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2026, period end 30 Jun 2026
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 18 Oct 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.